Exicure, Inc. (XCUR) |
| 1.0625 -0.028 (-2.52%) 10-27 11:38 |
| Open: | 1.065 |
| High: | 1.07 |
| Low: | 1.01 |
| Volume: | 9,017 |
| Market Cap: | 7(M) |
| PE Ratio: | -0.8 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.30 |
| Resistance 1: | 1.16 |
| Pivot price: | 1.08 |
| Support 1: | 0.94 |
| Support 2: | 0.78 |
| 52w High: | 9.48 |
| 52w Low: | 0.936 |
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Financials
| EPS | -1.310 |
| Book Value | 0.150 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.192 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -30.3 |
| Return on Equity (ttm) | -168.4 |
Company news
Fri, 23 Oct 2026
Exicure, Inc. Estimates – NASDAQ:XCUR - TradingView
Mon, 28 Sep 2026
Exicure Inc. (XCUR) Slips to $1.22 as Shares Press Against Nearby Support - Schiff Line - siam.in
Wed, 16 Sep 2026
Exicure Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Mon, 03 Aug 2026
Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics - Quiver Quantitative
Mon, 03 Aug 2026
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Yahoo Finance
Mon, 01 Jun 2026
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
